The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Next-generation superparamagnetic iron oxide nanoparticles for cancer theranostics
Open accessAbstract
Superparamagnetic iron oxide (SPIO) nanoparticles have been intensively studied for the development of contrast agents in MRI. First-generation SPIO nanoparticles had diagnostic capabilities only, whereas a new generation of SPIO nanoparticle has multifunctional characteristics for combined therapeutic and diagnostic applications. These theranostic nanoparticles hold great potential for image-guided cancer therapies. In particular, polymer-coated theranostic SPIO nanoparticles have enjoyed increasing attention as a result of good biocompatibility, biodegradability and versatile functionality endowed by polymeric matrices. This review provides an overview of recently developed polymer-coated multifunctional SPIO nanoparticles for cancer theranostics and discusses current challenges and future perspectives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SPION have been loaded with many different therapeutics drugs. Especially anticancer agents have been employed, ranging from standard low molecular weight chemotherapeutics, such as doxorubicin, to more advanced therapeutic compounds, such as siRNA [237, 238].”
From Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications (2019) · cites this paper as [238]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer
Harisinghani, M. G., Barentsz, J., Hahn, P. F., Deserno, W. M., Tabatabaei, S., van de Kaa, C. H., de la Rosette, J., & Weissleder, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022749 · Cited by 1,971
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,759
Zanganeh, S., Hutter, G., Spitler, R., Lenkov, O., Mahmoudi, M., Shaw, A., Pajarinen, J. S., Nejadnik, H., Goodman, S., Moseley, M., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.168 · Cited by 1,647
Self-citationLe Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137
Molecular targeted therapies in hepatocellular carcinoma†
Llovet, J. M., & Bruix, J. (2008) · Hepatology · doi:10.1002/hep.22506 · Cited by 1,011
Polymer-encapsulated organic nanoparticles for fluorescence and photoacoustic imaging
Li, K., & Liu, B. (2014) · Chemical Society Reviews · doi:10.1039/c4cs00014e · Cited by 1,000
Self-citation
Research works printed but not linked: 1
- Siegel, 2016, Cancer statistics, CA. Cancer J. Clin., 66, 7
Cited by
Sorted by citations
Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications
Dadfar, S. M., Roemhild, K., Drude, N. I., von Stillfried, S., Knüchel, R., Kiessling, F., & Lammers, T. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.005 · Cited by 1,181
Application of Nanomaterials in Biomedical Imaging and Cancer Therapy
Siddique, S., & Chow, J. C. L. (2020) · Nanomaterials · doi:10.3390/nano10091700 · Cited by 411
Responsive biomaterials: optimizing control of cancer immunotherapy
Xue, L., Thatte, A. S., Mai, D., Haley, R. M., Gong, N., Han, X., Wang, K., Sheppard, N. C., June, C. H., & Mitchell, M. J. (2023) · Nature Reviews Materials · doi:10.1038/s41578-023-00617-2 · Cited by 219
Recent advances in theranostic polymeric nanoparticles for cancer treatment: A review
Indoria, S., Singh, V., & Hsieh, M.-F. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119314 · Cited by 168
Khafaji, M., Zamani, M., Golizadeh, M., & Bavi, O. (2019) · Biophysical Reviews · doi:10.1007/s12551-019-00532-3 · Cited by 155
Metadata
- Authors
- Li, K., Nejadnik, H., & Daldrup-Link, H. E.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Li, Kai
- Daldrup-Link, Heike E.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 22
- Issue
- 9
- Pages
- 1421-1429
- ISSN
- 1359-6446 (ISSN-L)
- PMC
- PMC5610947
- OpenAlex
- W2608879075
- Cited by
- 139
- References
- 62
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 12 · 2023: 16 · 2022: 21 · 2021: 24 · 2020: 18 · 2019: 17 · 2018: 17 · 2017: 2
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Drug Discovery Today (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (NCI) (R21CA190196)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (R21AR066302, 2R01AR054458)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (R01 HD081123-01A1)
- Agency for Science, Technology and Research (A*STAR, Singapore)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › Characterization and Applications of Magnetic Nanoparticles
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- superparamagnetic iron oxide nanoparticles, theranostics, cancer theranostics, polymer-coated nanoparticles, multifunctional nanoparticles, MRI contrast agents, image-guided cancer therapy, biocompatibility, biodegradability
- MeSH terms
- Theranostic Nanomedicine, Animals, Ferric Compounds, Humans, Hyperthermia, Induced, Neoplasms, Phototherapy, Genetic Therapy, Metal Nanoparticles, Magnetic Phenomena
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
